Alzamend raises $4M, funds MGH Phase II Lithium in Brain but faces going concern risk

Alzamend Neuro, Inc. (NASDAQ: ALZN) - Quick internal read

Snapshot - what's happening inside

* Cash position improved to $5,620,872 as of July 31, 2025 (up from $3,948,658 on April 30, 2025).
* Company raised $4,035,000 in the quarter from Series C convertible preferred stock financings (net proceeds).
* Clinical activity ramping: Phase II "Lithium in Brain" imaging study with Massachusetts General Hospital underway; first healthy subject dosed in May 2025. AL001 has prior positive Phase IIA topline and full data announced.

Key balance sheet & capital facts

* Total assets: $6,326,751 (July 31, 2025).
* Working capital: $4,945,519 (derived from current assets $5,928,830 less current liabilities $983,311).
* Stockholders' equity: $5,343,440; accumulated deficit: $(61,237,945).
* Common shares outstanding: 3,139,861 as of Sept 10, 2025 (post conversions and reverse splits).
* Significant equity activity: Orchid converted 575.7176 shares of Series C into 2,117,699 common shares; Ault Lending converted 564.75528 Series B into 243,429 common shares during the quarter.

Income statement - headline numbers (3 months ended July 31, 2025)

* Total operating expenses: $2,700,201 (vs $962,405 in prior-year quarter).
* Research & development expense: $1,740,867 (up 743% YoY; prior: $206,571). Clinical trial fees = $1,661,384 of R&D spend this quarter.
* General & administrative expense: $959,334 (up 27% YoY).
* Net loss: $(2,702,684) (vs $(974,411) prior year).
* Cash used in operating activities: $(2,362,786) for the quarter.
* Basic & diluted net loss per share: $(1.28) (note prior-year per-share number was distorted by very different share count: $(11.42)).

Positive aspects of the income statement / operations

* R&D acceleration reflects clear advancement into a clinical, resource-intensive phase - $1.66M was directed to the Phase II brain imaging study with MGH (evidence of active clinical progression).
* Cash runway extended in the short term by $4.035M Series C financing - cash increased by $1.672M in the quarter.
* Interest expense is negligible (only $2,483 for the quarter), so financing costs currently light relative to operating burn.

Negative aspects of the income statement / operations

* Heavy quarterly burn: $2.36M cash used in operations and a $2.7M GAAP loss - company expects continued losses.
* Rapid increase in R&D and G&A drove a 181% increase in total operating expenses YoY - higher spend without revenue (no product revenue to date).
* Large accumulated deficit: $(61.2M) indicates long history of cash consumption.
* Per-share loss metrics are volatile and have been materially affected by large equity transactions and preferred conversions (dilution risk remains high).

Operational and governance risks - items to watch

* Going concern: management explicitly states substantial doubt about ability to continue as a going concern - additional financing is required within the next 12 months.
* Internal controls: management identified a material weakness - insufficient accounting resources to review manual journal entries and reconciliations; remediation ongoing but not complete.
* ALZN002 disruption: CRO Biorasi terminated the contract for the ALZN002 trial; replacement CRO is being sought - this slows immunotherapy program progress.
* License milestones and royalties: multiple license agreements require future milestone payments (example: up to $10,000,000 on FDA NDA approval for AL001 and similar multi-million dollar milestones for ALZN002) and ongoing royalties (4.5% for AL001, 4% for ALZN002, 3% for additional AL001 indications) - meaningful cash obligations if/when milestones trigger.

Capital structure and dilution

* Active preferred stock issuance and conversions dramatically increased common share count this year (multiple reverse splits and conversions occurred). Weighted average common shares for the quarter were 2,106,036 (vs 85,314 prior year).
* Series C had 15.7176 issued and then significant closings produced net proceeds of $4,035,000; warrants and voting floors create potential future dilution and governance considerations.

Near-term catalysts & metrics to monitor

* Progress and data readouts from the "Lithium in Brain" Phase II imaging study (MGH) - clinical results will materially affect valuation and fundraising ability.
* Replacement CRO selection and status/timing of ALZN002 Phase I/IIA trial continuation.
* Cash burn vs. additional financing: watch monthly burn rate and timing/size of any equity or debt raises; management plans to pursue public or private equity and debt financings.
* Remediation of internal control weaknesses - impacts audit/compliance risk and investor confidence.
* Potential milestone payments under license agreements that could require cash or trigger further financing/dilution if payments fall due.

Bottom line (straight)

* Alzamend is transitioning from pre-revenue R&D to an active clinical stage: that drives higher R&D spend (good for program progress) but sharply increases cash burn and near-term financing needs.
* The company secured a $4.035M Series C infusion this quarter and now holds $5.62M cash - short-term runway improved but not guaranteed beyond 12 months given current burn and stated going-concern doubt.
* Clinical progress (MGH partnership, Phase II dosing) is the core positive. Key risks are ongoing cash needs, governance/control weaknesses, CRO instability for ALZN002, and dilution from preferred conversions and future financings.

If you want, I can prepare a 1‑page investor-ready summary (one slide) or a short checklist of immediate management actions to stabilize controls and extend runway.